Founded with a mission to revolutionize cell therapy manufacturing, PBS Biotech specializes in the design and production of single-use bioreactor systems. These systems utilize patented air and liquid mixing technology to enhance cell culture processing, crucial for research, development, and commercialization of biological drugs and vaccines. The company focuses on providing scalable solutions for allogeneic therapies derived from cells like induced pluripotent stem cells, mesenchymal stem cells, and CAR-T or NK cells.
PBS Biotech has garnered attention for its innovative approach to bioreactor design, attracting notable investors and industry experts. The company's products have significantly impacted the pharmaceutical industry by enabling more efficient and scalable manufacturing processes for cell-based therapies. Their contributions have facilitated advancements in clinical trials and the broader field of regenerative medicine, positioning PBS Biotech as a key player in the biotechnology equipment sector.
